Last updated on January 2019

Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study


Brief description of study

This study will provide continuing availability to tazemetostat as a single agent to subjects who have completed their participation in an antecedent tazemetostat study (either with monotherapy or combination therapy). In addition, long-term safety and overall survival will be collected.

Clinical Study Identifier: NCT02875548

Find a site near you

Start Over

Epizyme

Tucson, AZ United States
  Connect »

Epizyme

Bordeaux, France
  Connect »

Epizyme

Montpellier, France
  Connect »

Epizyme

Villejuif Cedex, France
  Connect »

Epizyme

New York, NY United States
  Connect »

Epizyme

Lille, France
  Connect »

Epizyme

Rouen, France
  Connect »

Epizyme

Leicester, United Kingdom
  Connect »

Epizyme

London, United Kingdom
  Connect »

Epizyme

Clayton, Australia
  Connect »

Epizyme

East Melbourne, Australia
  Connect »

Epizyme

Pierre-Bénite, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.